- Metroprolol succinate
-
- $1.00 / 1g
-
2025-08-08
- CAS:98418-47-4
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 1kg/month
- Metroprolol succinate
-
- $0.00 / 25KG
-
2025-08-08
- CAS:98418-47-4
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
- Metroprolol succinate
-
- $2.00 / 100kg
-
2025-07-29
- CAS:98418-47-4
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| Product Name: | Metroprolol succinate | | Synonyms: | Metoprolol Succinate (200 mg);METOPROLOL SUCCINATE;metroprolol succinate;2-Propanol, 1-(4-(2-Methoxyethyl)phenoxy)-3-((1-Methylethyl)aMino)-, (+-)-, butanedioate (2:1) (salt);Metoprolol Succinate (ToprolX);rolol succinate;Metoprolol Succinate (200 mg)F0C4150.998mg/mg(ai);1-[4-(2-Methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-2-propanol Butanedioate | | CAS: | 98418-47-4 | | MF: | 2C15H25NO3.C4H6O4 | | MW: | 652.82 | | EINECS: | 620-476-9 | | Product Categories: | | | Mol File: | 98418-47-4.mol |  |
| | Metroprolol succinate Chemical Properties |
| Melting point | 136-138°C | | storage temp. | Hygroscopic, Refrigerator, under inert atmosphere | | solubility | Freely soluble in water, soluble in methanol, slightly soluble in ethanol (96 per cent), very slightly soluble in ethyl acetate. | | form | Solid | | color | White to Off-White | | Stability: | Hygroscopic | | InChI | InChI=1S/2C15H25NO3.C4H6O4/c2*1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3;5-3(6)1-2-4(7)8/h2*4-7,12,14,16-17H,8-11H2,1-3H3;1-2H2,(H,5,6)(H,7,8) | | InChIKey | RGHAZVBIOOEVQX-UHFFFAOYSA-N | | SMILES | C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1.C(C(=O)O)CC(=O)O.C1(OCC(O)CNC(C)C)=CC=C(CCOC)C=C1 |
| | Metroprolol succinate Usage And Synthesis |
| Antihypertensives | At present, it is a selective β1 receptor blocker which is widely used for high blood pressure, coronary heart disease, chronic heart failure and cardiac arrhythmia treatment,Metroprolol succinate is a conventional tablet of metoprolol , its elimination half-life is shorter than others, about 3 to 4 hours, so the plasma drug concentration fluctuation is great, and2 to 4 times daily medication is necessary. To overcome these disadvantages, AstraZeneca's recently introduced metoprolol succinate sustained-release tablet is a new depot metoprolol , once-daily medication can guarantee 24 hours of constant metoprolol plasma concentration and β1-receptor blocking effect .On clinical pharmacology and therapeutics ,it has many advantages. Clinically it is used for the treatment of hypertension, angina pectoris, chronic heart failure with left ventricular systolic dysfunction and stable symptoms.
Oral, once a day, take preferably in the morning, it can be broken apart and taken, but you can not chew or crush,at least half a cup of liquid should be taken for delivery . At the same time food intake does not affect their bioavailability. Dosage should be individualized to avoid bradycardia. The following is an effective medication guide: high blood pressure: 47.5~95mg, once daily. Taking 95mg of metoprolol succinate sustained-release tablets may be ineffective in patients ,combine them with other anti-hypertensive drugs, preferably diuretics and dihydropyridine calcium antagonists, or increase the dose. Angina: 95~190mg, once daily.Combine them with nitrates or increase the dose if it is needed.
The above information is edited by the chemicalbook of Tian Ye.
| | Uses | High blood pressure medication.
| | Chemical Properties | White or almost white, crystalline powder. | | Uses | Anti - hypertensives | | Uses | Metoprolol Succinate is used in the treatment of patients suffering from chronic heart failure, as well as to treat blood pressure from mild hypertension. β-adrenoceptor antagonist or β-blocker. | | Definition | ChEBI: Metoprolol succinate is an alcohol and a member of phenols. | | Brand name | Toprol (AstraZeneca). | | in vivo | Metoprolol (2.5 mg/kg/h; infusion; 11 weeks) reduces proinflammatory cytokines and atherosclerosis in ApoE?/? Mice[1].
Metoprolol (15 mg/kg/q12h; i.g.; 5 days) shows anti-inflammation and anti-virus effects in murine model with coxsackievirus B3-induced viral myocarditis[2].
Metoprolol (2.5 mg/kg; i.v.; 3 bolus injections) significantly decreased activated caspase-9 protein expression and inhibits myocardial apoptosis in coronary microembolization (CME) rats[4]. | Animal Model: | Male ApoE?/? mice[1] | | Dosage: | 2.5?mg/kg/h | | Administration: | Via osmotic minipumps, 11 weeks | | Result: | Significantly reduced atherosclerotic plaque area in thoracic aorta, reduced serum TNFα and the chemokine CXCL1 as well as decreasing the macrophage content in the plaques. |
| Animal Model: | Balb/c mice, coxsackievirus B3 (CVB3) induced viral myocarditis (VMC) model[2] | | Dosage: | 15 mg/kg/q12h
| | Administration: | Oral gavage, 5 consecutive days | | Result: | Reduced pathological scores of VMC induced by CVB3 infection, protected the myocardium against viral damage by reducing serum cTn-I levels. Decreased the levels of myocardial pro-inflammatory cytokines and increase the expression of anti-inflammatory cytokine. Significantly decreased myocardial virus titers. |
| | IC 50 | β1 adrenoceptor |
| | Metroprolol succinate Preparation Products And Raw materials |
|